

Organized by



Under the auspices of



In collaboration with



IMMUNOTHERAPY ¹⁰ YEARS ²⁰²⁴ BRIDGE

Naples (Italy)

December 4th-5th, 2024

Royal Continental Hotel

www.melanomabridge.org - info@melanomabridge.org

GENERAL INFORMATION

CME PROVIDER

T&C Srl

Via Ciovasso, 4 - 20121 Milan

Cell. 334/1837054

www.tccompany.it



ORGANIZING SECRETARIAT

Vivenko Srl Società Benefit

Via De Amicis, 42 - 20123 Milan

www.vivenko.net

info@melanomabridge.org



OFFICIAL LANGUAGE

The official language is English.

REGISTRATION

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific sessions
- congress kit (badge, notepad, pen)
- coffee breaks and lunches

For information and registration, please, send an email to:


registration@melanomabridge.org

GENERAL INFORMATION

CONGRESS VENUE

Royal Continental Hotel

Via Partenope, 38 - 80121 Naples



INTERNATIONAL
AIRPORT

RAILWAY
STATION

CONGRESS
VENUE

SCIENTIFIC RATIONAL

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies, the Immunotherapy beyond T cells and also the novel platforms and approaches for immune monitoring will be exhaustively discussed.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

SCIENTIFIC PROGRAM

DAY 1 Wednesday, Dec 4th

10.00 am Introduction and Objectives
Paolo A. Ascierto

SITvC SESSION

TIL ADVANCEMENTS: CAR-T AND TILS

Chairpersons: **Leisha A Emens, Stephanie L. Goff**

10.10 am Overview on Cell Therapy and Enhancements for CAR T-cell activity
Avery D Posey

10.25 am Q&A

10.30 am Novel technologies to enhance immune cells functions
Timothy Lu

10.45 am Q&A

10.50 am CAR-T Therapy
Renier Brentjens

11.05 am Q&A

11.10 am TIL for melanoma: the time is now
Stephanie L. Goff

11.25 am Q&A

11.40 am The best of SITC 2024
Paolo A. Ascierto

11.45 am Q&A

11.50 pm LECTURE

The Evolutionary Landscape of Gastrointestinal Treatment

Antonio Avallone

Immunotherapy in treatment of endometrial cancer

Domenica Lorusso*

12.20 pm SYMPOSIUM

New Evidence in Oncology from Advanced to Early stages - Renal Cancer

Sarah Scagliarini*

Frontiers in Thoracic Oncology: transforming Early-Syge Care and Targeted Therapies for Improved Patient Outcomes

Alessandro Morabito*

Immunotherapy in GI tumors: what we have learned

Nicola Silvestris

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 1 Wednesday, Dec 4th

1.10 pm **Lunch****

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov**

2.10 pm Should we continue to add something to checkpoint inhibitors or we need to change strategy?

Hussein Tawbi vs Omid Hamid

2.35 pm Should we do combination immunotherapy trials with drugs that lack single agent activity? Yes or no

Bernard A. Fox vs Igor Puzanov

3.05 pm ADCs VS Bispecific

Leisha A. Emens vs Samir Khleif

SESSION 2

IMMUNOTHERAPY BEYOND T CELLS AND IMMUNOTHERAPY BEYOND CLASSICAL T CELLS

Chairpersons: **Alfredo Budillon, Luigi Buonaguro**

3.25 pm B cells

Chrystal M. Paulos

3.40 pm NK Cell

Timothy Lu

3.55 pm Myeloid Cells

Jennifer Guerriero

4.10 pm Neutrophil Cells

Brahm Segal

4.25 pm Macrophages as tools and targets in cancer therapy

Cecilia Garlanda

4.40 pm Armored CAR-T Cells

Renier Brentjens

4.55 pm **DISCUSSION Round Table**

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 1 Wednesday, Dec 4th

SESSION 3

IMMUNE MONITORING: NOVEL PLATFORMS AND APPROACHES

Chairpersons: **Elizabeth M. Burton**, **Lisa H. Butterfield**

- 5.30 pm Landscape/overview of trends in biomarker proposals - CIMAC/SITC
Holden Terry Maecker
- 5.45 pm Integrating data across biomarker platforms
Christine N. Spencer
- 6.00 pm Leveraging AI to integrate image based analyses
Lacey Padron
- 6.15 pm **DISCUSSION Round Table**

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 2 Thursday, Dec 5th

SESSION 4

ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: **Omid Hamid, Sandro Pignata**

9.30 am Pancreatic Cancer

Renato Ostuni

9.40 am Lung cancer

Alessandro Morabito

9.50 am Renal cancer

Tony Choueiri

10.00 am GU cancer

Akash Patnaik

10.10 am GI cancer

Gregory B. Lesinski

10.20 am Endometrial Cancer

Emese Zsiros

10.30 am Ovarian Cancer

Kunle Odunsi

10.40 am Head & Neck

Robert L. Ferris

10.50 am **DISCUSSION Round Table**

11.25 pm **Coffee Break****

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov**

11.40 am No role for first chemo-immuno VS vegf/immuno first line

Robert L. Ferris vs Toni Choueiri

12.05 pm Pre-treatment predictive biomarkers: INF g vs. Immunoscore vs. multiplex IF/next-generation spatial biology

Christian Blank vs Jerome Galon vs Janis Taube

12.40 pm Do we need vaccines? Yes or no

Pawel Kalinski vs Stephen Schoenberger

1.05 pm **Lunch****

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 2 Thursday, Dec 5th

2.00 pm **SYMPOSIUM**
Non-Melanoma Skin Cancers
Paolo A. Ascierto, Dirk Schadendorf

SESSION 5

NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: **Paolo A. Ascierto, Elizabeth M. Burton**

2.50 pm INNOVATE summary
Paolo A. Ascierto

3.05 pm Breast
Leisha A. Emens

3.20 pm Lung
Tina Cascone

3.35 pm Melanoma
Christian Blank

3.50 pm Non Melanoma Skin Cancers
Neil Gross

4.05 pm Translational insights from anti-LAG3
Elizabeth M. Burton

4.20 pm Pan tumor path response assessment
Julie Stein Deutsch

16.35 pm **DISCUSSION Round Table**

5.05 pm **Conclusion**

PRESIDENCY



Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy



Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)



Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US



Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy

Carlo Bifulco

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Christian Blank

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

SCIENTIFIC BOARD

Elizabeth M. Burton

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield

Adjunct Professor of Microbiology and Immunology, University of California San Francisco, CA, US

Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Mary Dean

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria

Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US

Reinhard Dummer

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, Netherlands

Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Jeffrey E. Gershenwald

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

Omid Hamid

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

SCIENTIFIC BOARD

Samir N. Khleif

Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Dirk Schadendorf

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US